225937-10-0
基本信息
DL-兒茶素
(+)-兒茶素,兒茶酚,兒茶酸,鄰苯二酚
D(+)-兒茶精
D(+)-兒茶素(四水)
D(+)-兒茶酸
反式-3,3ˊ,4ˊ,4,7-五羥基黃烷
四水合-D(+)兒茶素
(+)-兒茶精
(+)-兒茶素(一水物)
(2R,3S)-2-(3,4-二羥基苯基)-3,4-二氫-1(2H)-苯并吡喃-3,5,7-三醇一水物
(2R,3S)-2-(3,4-DIHYDROXYPHENYL)-3,4-DIHYDRO-1(2H)-BENZOPYRAN-3,5,7-TRIOL
(2R,3S)-2-(3,4-DIHYDROXYPHENYL)-3,4-DIHYDRO-1(2H)-BENZOPYRAN-3,5,7-TRIOL HYDRATE
(+)-3,3',4',5,7-FLAVANPENTOL HYDRATE
(+)-3,3',4',5,7-FLAVANPENTOL MONOHYDRATE
3,3',4',5,7-PENTAHYDROXYFLAVANE HYDRATE
(+)-C
(+)-CATECHIN HYDRATE
(+)-CATECHIN MONOHYDRATE
CATECHOL (FLAVAN), HYDRATE
CATECHUIC ACID (HYDRATE)
(+)-CYANIDOL-3
(+)-CYANIDOL-3, HYDRATE
CYANIDOL HYDRATE
D-CATECHIN
D-(+)-CATECHIN HYDRATE
D-CATECHIN HYDRATE
D-CATECHOL HYDRATE
(+)-TRANS-3,3',4',5,7-PENTAHYDROXYFLAVANE HYDRATE
TRANS-3,3',4',5,7-PENTAHYDROXYFLAVANE HYDRATE
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | 46302 | (+)-兒茶素水合物 (+)-Catechin hydrate, Thermo Scientific Chemicals | 225937-10-0 | 1g | 876元 |
2024/11/08 | 46302 | (+)-兒茶素水合物 (+)-Catechin hydrate, Thermo Scientific Chemicals | 225937-10-0 | 5g | 3395元 |
2024/11/08 | C0705 | (+)-兒茶素 水合物 (+)-Catechin Hydrate | 225937-10-0 | 1g | 130元 |
常見問題列表
COX-1 1.4 μM (IC 50 ) |
(+)-Catechin exhibits >95% inhibitory activity at 70 μg/mL against cyclooxygenase-1 (COX-1) with an IC 50 of 1.4 μM. A dose-dependent reduction in color is observed after 24 hours of treatment with (+)-Catechin, and 54.76% of the cells are dead at the highest concentration of (+)-Catechin tested (160 μg/mL) whereas the IC 50 of (+)-Catechin is achieved at 127.62 μg/mL (+)-Catechin. A dose- and time-dependent increase in the induction of apoptosis is observed when MCF-7 cells are treated with (+)-Catechin. When compare to the control cells at 24 hours, 40.7 and 41.16% of the cells treated with 150 μg/mL and 300 μg/mL (+)-Catechin, respectively, undergo apoptosis. The expression levels of Caspase-3 , -8 , and -9 and p53 in MCF-7 cells treated with 150 μg/mL (+)-Catechin for 24 h increase by 5.81, 1.42, 3.29, and 2.68 fold, respectively, as compare to the levels in untreated control cells.
Animals treated with (+)-Catechin at the lowest tested dose, i.e., 50 mg/kg, p.o. have spent comparatively more time in exploring the novel object in the choice trial, however, the difference is not statistically significant. (+)-Catechin prevents the time-induced episodic memory deficits in a dose-dependent manner, the most effective being 200 mg/kg, p.o.. Treatment with (+)-Catechin prevents the rise in MPO level compare to DOX alone treatment group (21.98±9.44 and 36.76±4.39% in the hippocampus and the frontal cortex respectively).